The WTA tournament welcomes another partner on board before the start of the tournament: the global biopharmaceutical company Vanda Pharmaceuticals. Vanda is developing important new medicines to improve the lives of patients. They use new technologies, including genetics and genomics, to inform their drug discovery, clinical trials and commercial positioning of their compounds.
“The MSC Hamburg Ladies Open presents a wonderful opportunity for Vanda Pharmaceuticals to showcase our company in a setting defined by tradition and excellence. The tournament’s long-standing history and the unique atmosphere of the city of Hamburg provide an ideal platform for our engagement. Just as in top-level tennis, perseverance, and innovation are essential in pharmaceutical research — values that we share at Vanda Pharmaceuticals“, says Vasilios Polymeropoulos, Vice President of Vanda Pharmaceuticals.